Polyoxyethylene stearate (POES)
(Synonyms: 聚氧乙烯硬脂酸酯; POES) 目录号 : GC33151
聚氧乙烯硬脂酸酯（POES）（POES）是一种非离子型乳化剂。
Cas No.:9004-99-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Polyoxyethylene stearate (POES) is a non-ionic emulsifying agent.
Polyoxyethylene stearate has been recommended as an additive to the radiolabelled 7H12 Middlebrook TB media and as such has been shown to enhance growth of mycobacteria in the radiometric BACTEC rapid culture system. Polyoxyethylene (50) stearate produces the greatest enhancement in growth and reduction in the time taken to detect growth for M. tuberculosis and polyoxyethylene (30) stearate and polyoxyethylene (JL) stearate for species of mycobacteria other than M. tuberculosis[1]. Polyoxyethylene stearate inhibits P-gp mediated efflux in a concentration dependent manner mainly by modulating substrate-stimulated P-gp ATPase activity[2]. Polyoxyethylene 40 stearate reduces vinblastine sulfate efllux. The cytotoxicity of vinblastine to K562/ADR cells is significantly enhanced when the cells are cotreated with 100 or 150 μg/mL polyoxyethylene 40 stearate[3].
Polyoxyethylene stearate is potentially useful as a pharmaceutical ingredient to improve the oral bioavailability of coadministered P-gp substrates and substrates for certain CYP isoforms[2]. The average tumor volume and average tumor weight are significantly less in the polyoxyethylene 40 stearate+vinblastine group. The inhibition rate for tumor growth is increased from 0.06 (vinblastine group) to 0.84 (vinblastine+polyoxyethylene 40 stearate group)[3].
[1]. Cutler RR, et al. The effect of polyoxyethylene stearate (POES) on the growth of mycobacteria in radiometric 7H12 Middlebrook TB medium. Tubercle. 1987 Sep;68(3):209-20. [2]. Zhu S, et al. Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450. Eur J Pharm Sci. 2009 Jul 12;37(5):573-80. [3]. Luo L, et al. Polyoxyethylene 40 stearate modulates multidrug resistance and enhances antitumor activity of vinblastine sulfate. AAPS J. 2007 Oct 5;9(3):E329-35.
Cell experiment: | Polyoxyethylene 40 stearate is added to the test vinblastine solution. The cytotoxicity of vinblastine to K562/ADR cells is then assessed. The final concentrations of polyoxyethylene 40 stearate are 0, 50, 100, and 150 μg/mL. After 8 hours of treatment, cells are incubated for 4 hours in the presence of MTT reagent and then lysed with DMSO. Absorbance is measured at 490 nM[3]. |
Animal experiment: | Mice: Polyoxyethylene 40 stearate and vinblastine are dissolved in 0.9% sodium chloride solution, yielding a solution of 200 μg/mL VBL and 150 μg/mL PS40. The drug is injected subcutaneously in a volume of 0.1 mL per 10 g of body weight at a dosage of 2 mg/kg vinblastine and 1.5 mg/kg polyoxyethylene 40 stearate around the tumor every other day for 8 days. The volume of tumors and the weight of mice are measured every day from the day the tumors are formed[3]. |
References: [1]. Cutler RR, et al. The effect of polyoxyethylene stearate (POES) on the growth of mycobacteria in radiometric 7H12 Middlebrook TB medium. Tubercle. 1987 Sep;68(3):209-20. | |
| Cas No. | 9004-99-3 | SDF | |
| 别名 | 聚氧乙烯硬脂酸酯; POES | ||
| Canonical SMILES | O=C(OCCO)CCCCCCCCCCCCCCCCC.[n].[n].[=].[10] | ||
| 分子式 | C20H40O3 | 分子量 | 328.53 |
| 溶解度 | DMSO : ≥ 49 mg/mL (149.15 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0439 mL | 15.2193 mL | 30.4386 mL |
| 5 mM | 0.6088 mL | 3.0439 mL | 6.0877 mL |
| 10 mM | 0.3044 mL | 1.5219 mL | 3.0439 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet